{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:11:48Z","timestamp":1792782708050,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Friedrich-Schiller-Universit\u00e4t Jena","id":[{"id":"https:\/\/ror.org\/05qpz1x62","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schmerz"],"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>In der ambulanten Palliativversorgung (PV) von onkologisch erkrankten Patient:innen in Deutschland haben sich seit Jahren verschiedene Versorgungsformen etabliert. Es liegen bisher keine Daten vor, wie sich die Verordnungsraten (VO-Raten) von Analgetika und Supportiva in Abh\u00e4ngigkeit von der jeweiligen ambulanten PV-Form unterscheiden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodik<\/jats:title>\n                    <jats:p>In der retrospektiven Kohortenstudie wurden Daten von 158.035 zwischen 2016 und 2021 verstorbenen GKV-Versicherten (VS) mit fortgeschrittener onkologischer Erkrankung ausgewertet. Es wurden drei Gruppen analysiert: VS ohne ambulante PV, mit allgemeiner ambulanter PV oder besonders qualifizierter und koordinierter PV (AAPV\/BQKPmV) sowie mit spezialisierter ambulanter PV (SAPV). Die Untersuchung fokussierte auf die VO-Raten verschiedener Medikamentengruppen gem\u00e4\u00df ATC-Codes (Nichtopioid- und Opioidanalgetika, antineuropathische Medikation, Antiemetika, systemische Steroide, stuhlregulierende Medikamente) sowie deren Kombinationen im letzten Lebensmonat.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>SAPV-VS zeigten die h\u00f6chsten VO-Raten, z.\u202fB. starke Opioide (71,8\u202f%), gefolgt von AAPV\/BQKPmV (47,2\u202f%) und VS ohne PV (22,5\u202f%). Die VO-Raten f\u00fcr alle Supportiva zeigten \u00e4hnliche Muster. Ein umgekehrtes Muster wurde bei schwachen Opioiden beobachtet: SAPV (5,8\u202f%), AAPV\/BQKPmV (8,9\u202f%), keine PV (9,1\u202f%). Die leitliniengerechte Kombination von starken Opioidanalgetika und stuhlregulierender Medikation wurde in weniger als der H\u00e4lfte der F\u00e4lle in SAPV (44,2\u202f%) und noch seltener in AAPV\/BQKPmV (32,4\u202f%) umgesetzt.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diskussion<\/jats:title>\n                    <jats:p>Die Studie liefert erstmals umfassende Einblicke in die medikament\u00f6se Verordnungspraxis in der ambulanten PV im letzten Lebensmonat. Die hohen VO-Raten in der SAPV spiegeln eine intensivere medikament\u00f6se Behandlung von VS mit m\u00f6glicherweise komplexerer Symptomatik in dieser spezialisierten PV-Form wider.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00482-026-00968-z","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:07:10Z","timestamp":1789639630000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analgetika und Supportiva im letzten Lebensmonat","Analgesics and supportive care in the last month of life"],"prefix":"10.1007","author":[{"given":"Ekaterina","family":"Slotina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianka","family":"Ditscheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Marschall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Wedding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Freytag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"issue":"3","key":"968_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s12312-020-00794-z","volume":"35","author":"B Alt-Epping","year":"2020","unstructured":"Alt-Epping\u00a0B, Bausewein\u00a0C, Voltz\u00a0R et\u00a0al (2020) Aktualisierte S3-Leitlinie \u201ePalliativmedizin f\u00fcr Patienten mit einer nicht heilbaren Krebserkrankung\u201c. Forum 35(3):199\u2013204","journal-title":"Forum"},{"issue":"2","key":"968_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.pain.2011.10.028","volume":"153","author":"MI Bennett","year":"2012","unstructured":"Bennett\u00a0MI, Rayment\u00a0C, Hjermstad\u00a0M et\u00a0al (2012) Prevalence and aetiology of neuropathic pain in cancer patients: a\u00a0systematic review. Pain 153(2):359\u2013365","journal-title":"Pain"},{"issue":"12","key":"968_CR3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1055\/s-2007-993199","volume":"83","author":"F Bleeker","year":"2007","unstructured":"Bleeker\u00a0F, Kruschinski\u00a0C, Breull\u00a0A et\u00a0al (2007) Charakteristika haus\u00e4rztlicher Palliativpatienten. Z Allg Med 83(12):477\u2013482","journal-title":"Z Allg Med"},{"issue":"1","key":"968_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/pds.1678","volume":"18","author":"SD Borgsteede","year":"2009","unstructured":"Borgsteede\u00a0SD, Deliens\u00a0L, Zuurmond\u00a0WWA et\u00a0al (2009) Prescribing of pain medication in palliative care. A survey in general practice. Pharmacoepidemiology and drug safety 18(1):16\u201323","journal-title":"Pharmacoepidemiology and drug safety"},{"key":"968_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/2050312119841823","volume":"7","author":"A Charalambous","year":"2019","unstructured":"Charalambous\u00a0A, Zorpas\u00a0M, Cloconi\u00a0C et\u00a0al (2019) Healthcare professionals\u2019 perceptions on the use of opioid analgesics for the treatment of cancer-related pain in Cyprus: A\u00a0mixed-method study. SAGE open medicine 7:2050312119841823","journal-title":"SAGE open medicine"},{"key":"968_CR6","unstructured":"Statistisches Bundesamt (Destatis) Todesursachenstatistik 2021. https:\/\/www.destatis.de\/DE\/Presse\/Pressemitteilungen\/2022\/12\/PD22_544_23211.html"},{"issue":"12","key":"968_CR7","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1007\/s00103-020-03240-6","volume":"63","author":"B Ditscheid","year":"2020","unstructured":"Ditscheid\u00a0B, Krause\u00a0M, Lehmann\u00a0T et\u00a0al (2020) Palliative care at the end of life in Germany: Utilization and regional distribution (Palliativversorgung am Lebensende in Deutschland : Inanspruchnahme und regionale Verteilung). Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 63(12):1502\u20131510","journal-title":"Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz"},{"issue":"9","key":"968_CR8","first-page":"298","volume":"121","author":"B Ditscheid","year":"2024","unstructured":"Ditscheid\u00a0B, Krause\u00a0M, Marschall\u00a0U et\u00a0al (2024) Medical Specialties Providing Outpatient Palliative Care\u2011a Comparison Across Regions Based on German Statutory Health Insurance Claims Data. Deutsches Arzteblatt international 121(9):298\u2013299","journal-title":"Deutsches Arzteblatt international"},{"issue":"4","key":"968_CR9","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s00103-023-03683-7","volume":"66","author":"B Ditscheid","year":"2023","unstructured":"Ditscheid\u00a0B, Meissner\u00a0F, Gebel\u00a0C et\u00a0al (2023) Inanspruchnahme von Palliativversorgung am Lebensende in Deutschland: zeitlicher Verlauf (2016-2019) (Utilization of palliative care at the end of life in Germany: temporal trend (2016-2019) and regional variability). Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 66(4):432\u2013442","journal-title":"Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz"},{"issue":"3","key":"968_CR10","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s00482-016-0110-0","volume":"30","author":"P Engeser","year":"2016","unstructured":"Engeser\u00a0P, Kuate Fokan\u00a0F, Laux\u00a0G et\u00a0al (2016) Versorgung von Patienten mit Tumorschmerzen in haus\u00e4rztlichen Praxen in Deutschland. Der Schmerz 30(3):266\u2013272","journal-title":"Der Schmerz"},{"issue":"4","key":"968_CR11","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1080\/15360288.2023.2257674","volume":"37","author":"J Fleckner","year":"2023","unstructured":"Fleckner\u00a0J, Pettus\u00a0K, Vallath\u00a0N et\u00a0al (2023) Systematic Review on Barriers to Access Opioid Analgesics for Cancer Pain Management from the Health Worker Perspective. Journal of pain & palliative care pharmacotherapy 37(4):324\u2013335","journal-title":"Journal of pain & palliative care pharmacotherapy"},{"issue":"2","key":"968_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1177\/0269216318812633","volume":"33","author":"JJ Fulton","year":"2019","unstructured":"Fulton\u00a0JJ, LeBlanc\u00a0TW, Cutson\u00a0TM et\u00a0al (2019) Integrated outpatient palliative care for patients with advanced cancer: A\u00a0systematic review and meta-analysis. Palliative medicine 33(2):123\u2013134","journal-title":"Palliative medicine"},{"issue":"3","key":"968_CR13","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00432-021-03652-0","volume":"148","author":"N Heerde","year":"2022","unstructured":"Heerde\u00a0N, Hofmann\u00a0WK, Hofheinz\u00a0RD et\u00a0al (2022) Analysis of end-of-life treatment and physician perceptions at a university hospital in Germany. Journal of cancer research and clinical oncology 148(3):735\u2013742","journal-title":"Journal of cancer research and clinical oncology"},{"issue":"4","key":"968_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s004820050206","volume":"13","author":"E Heidemann","year":"1999","unstructured":"Heidemann\u00a0E (1999) Tumorpatienten in Deutschland: Was wissen wir \u00fcber Schmerzpr\u00e4valenzen? Der Schmerz 13(4):249\u2013252","journal-title":"Der Schmerz"},{"issue":"12","key":"968_CR15","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/S1470-2045(16)30577-0","volume":"17","author":"D Hui","year":"2016","unstructured":"Hui\u00a0D, Mori\u00a0M, Watanabe\u00a0SM et\u00a0al (2016) Referral criteria for outpatient specialty palliative cancer care: an international consensus. The Lancet Oncology 17(12):e552\u2013e559","journal-title":"The Lancet Oncology"},{"key":"968_CR16","unstructured":"Meyer I, Schubert I Dr. (2019) Inanspruchnahme von SAPV und weiteren palliativen Leistungen, Charakteristika der Leistungsempf\u00e4nger und Hinweise auf die Zielerreichung von SAPV in der Region Nordrhein. Bericht zur retrospektiven Sekund\u00e4rdatenanalyse (AP1.1) im Projekt APVEL \u2013 Ambulante Palliativ-Versorgung Evaluieren. https:\/\/innovationsfonds.g-ba.de\/downloads\/beschluss-dokumente\/2\/2020-04-03_APVEL_Ergebnisbericht.pdf"},{"key":"968_CR17","unstructured":"Kassen\u00e4rztliche Bundesvereinigung G\u2011S (2016) Vereinbarung nach \u00a7 87 Abs. 1b SGB V zur besonders qualifizierten und koordinierten palliativmedizinischen Versorgung."},{"issue":"1","key":"968_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-023-01231-3","volume":"22","author":"SH Loosen","year":"2023","unstructured":"Loosen\u00a0SH, Schwartz\u00a0J, Grewe\u00a0S et\u00a0al (2023) Drug landscape in patients receiving general outpatient palliative care in Germany: results from a retrospective analysis of 10,464 patients. BMC palliative care 22(1):118","journal-title":"BMC palliative care"},{"issue":"1","key":"968_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s004820170045","volume":"15","author":"H Munzinger","year":"2001","unstructured":"Munzinger\u00a0H, Horstkotte\u00a0E, Hoffmann\u00a0W (2001) Opioidanalgetika in der Behandlung ambulanter Tumorpatienten 1993 und 1996. Ergebnisse einer bev\u00f6lkerungsbezogenen Untersuchung. Schmerz 15(1):26\u201332","journal-title":"Schmerz (Berlin, Germany)"},{"issue":"2","key":"968_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1191\/0269216304pm852oa","volume":"18","author":"F Nauck","year":"2004","unstructured":"Nauck\u00a0F, Ostgathe\u00a0C, Klaschik\u00a0E et\u00a0al (2004) Drugs in palliative care: results from a representative survey in Germany. Palliative medicine 18(2):100\u2013107","journal-title":"Palliative medicine"},{"issue":"1","key":"968_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-022-00954-z","volume":"21","author":"T Peralta","year":"2022","unstructured":"Peralta\u00a0T, Castel-Branco\u00a0MM, Reis-Pina\u00a0P et\u00a0al (2022) Prescription trends at the end of life in a palliative care unit: observational study. BMC palliative care 21(1):65","journal-title":"BMC palliative care"},{"key":"968_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/20503121241269599","volume":"12","author":"E Slotina","year":"2024","unstructured":"Slotina\u00a0E, Ditscheid\u00a0B, Meissner\u00a0F et\u00a0al (2024) A refined ICD-10 diagnoses-based approach for retrospective analysis of potential palliative care need and coverage in claims data of deceased. SAGE Open Med 12:1\u201311","journal-title":"SAGE Open Med"},{"issue":"1","key":"968_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-020-00603-3","volume":"19","author":"K Stichling","year":"2020","unstructured":"Stichling\u00a0K, Krause\u00a0M, Ditscheid\u00a0B et\u00a0al (2020) Factors influencing GPs\u2019 perception of specialised palliative homecare (SPHC) importance - results of a\u00a0cross-sectional study. BMC palliative care 19(1):117","journal-title":"BMC palliative care"},{"issue":"6","key":"968_CR24","doi-asserted-by":"publisher","first-page":"e1058","DOI":"10.1002\/onco.13751","volume":"26","author":"J Vogt","year":"2021","unstructured":"Vogt\u00a0J, Beyer\u00a0F, Sistermanns\u00a0J et\u00a0al (2021) Symptom Burden and Palliative Care Needs of Patients with Incurable Cancer at Diagnosis and During the Disease Course. The oncologist 26(6):e1058\u2013e1065","journal-title":"The oncologist"},{"key":"968_CR25","doi-asserted-by":"crossref","unstructured":"Volberg C, Corzilius J, Maul J et al. (2024) Schmerztherapie in der deutschen spezialisierten ambulanten Palliativversorgung: Eine Querschnittsstudie zur Darstellung der aktuellen schmerzmedizinischen Versorgung von palliativen Patienten im h\u00e4uslichen Umfeld. Schmerz 38(5):317-327","DOI":"10.1007\/s00482-023-00693-x"},{"key":"968_CR26","volume-title":"WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents","author":"World Health Organization (WHO)","year":"2018","unstructured":"World Health Organization (WHO) (2018) WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. World Health Organization, Geneva"},{"key":"968_CR27","doi-asserted-by":"crossref","unstructured":"Zugaj MR, Z\u00fcger A, Ke\u00dfler J (2024) Einflussfaktoren auf das Einnahmeverhalten von Analgetika bei Patient*innen mit chronischen tumorassoziierten Schmerzen: Eine qualitative Pilotstudie unter Ber\u00fccksichtigung verschiedener Medikamentengruppen. Schmerz 38, 422\u2013432","DOI":"10.1007\/s00482-023-00765-y"}],"container-title":["Der Schmerz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-026-00968-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00482-026-00968-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-026-00968-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:07:15Z","timestamp":1789639635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00482-026-00968-z"}},"subtitle":["Retrospektive Analyse von ambulanten Verordnungen anhand der BARMER-Daten von Versicherten mit einer onkologischen Erkrankung (2016\u20132021)","Retrospective analysis of outpatient prescriptions using BARMER data from patients with oncological diseases (2016\u20132021)"],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":27,"alternative-id":["968"],"URL":"https:\/\/doi.org\/10.1007\/s00482-026-00968-z","relation":{},"ISSN":["0932-433X","1432-2129"],"issn-type":[{"value":"0932-433X","type":"print"},{"value":"1432-2129","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"13 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"U.\u00a0Wedding: Facharzt f\u00fcr Innere Medizin mit den Schwerpunkten H\u00e4matologie und internistische Onkologie sowie Zusatzqualifikation in Palliativmedizin, erbringt Leistungen in der allgemeinen und spezialisierten ambulanten und station\u00e4ren Palliativversorgung. Er gibt zudem an, stellvertretender Sprecher der Arbeitsgemeinschaft Palliativmedizin (AG Palliativmedizin) der Deutschen Krebsgesellschaft (DKG) zu sein. W.\u00a0Meissner erhielt Honorare f\u00fcr Vortr\u00e4ge oder Beratungen von Merck, Sanofi, MSD, Tafalgie, Kyowa, Mundipharma, Gr\u00fcnenthal, Ethypharm. Seine Institution erhielt Forschungsunterst\u00fctzung von der European Commission, dem Gemeinsamen Bundesausschuss (G-BA), Medtronic, Pfizer, Mundipharma, Gr\u00fcnenthal, Vertanical. E.\u00a0Slotina, B.\u00a0Ditscheid, F.\u00a0Meissner, U.\u00a0Marschall und A.\u00a0Freytag geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die vorliegende Studie ist Teil des pallCompare-Projekts (01VSF19026). Die ethische Genehmigung wurde von der Ethikkommission des Universit\u00e4tsklinikums Jena erteilt (Reg.-Nr. 2021-2162-Daten). Eine Einwilligung der Patienten war nicht erforderlich. Die Studie wurde im Deutschen Register Klinischer Studien registriert (DRKS00024133). Alle Methoden wurden in \u00dcbereinstimmung mit den relevanten Richtlinien und Vorschriften gem\u00e4\u00df der Deklaration von Helsinki durchgef\u00fchrt.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}